

Registered Office:

Plot No. PF/21, Nr. Acme Pharma,
Opp. Teva Pharma, Sanand GIDC - II,
Sanand, Ahmedabad – 382110, Gujarat (INDIA)

CIN: L24230GJ2015PLC085451

Date: July 16, 2024

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400051.

Subject: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: Sotac Pharmaceuticals Limited (SYMBOL/ISIN: SOTAC/ INE002D01012)

Dear Sir/Madam,

In terms of Regulation 30 read with Para B of Part A of Schedule III to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, We, **Sotac Pharmaceuticals Limited** (“The Company”), wish to inform that Sotac Lifesciences Private Limited, subsidiary company of Sotac Pharmaceuticals Limited (“Sotac”) has entered into a Manufacturing Agreement (**Loan License Contract**) dated 16th July 2024 for production of agreed volume or quantities for ready-mix materials used for coating of pharmaceutical tablets (“the Products”) per year for next 10 years at mutually agreed manufacturing facility situated at Plot No. PF 59, Sanand GIDC II, Charal Industrial Estate, Sanand, Ahmedabad, Gujarat (“the Facility”) exclusively for Kerry Ingredients India Private Limited (“Kerry”) which will attribute towards profitability of the Company.

Kerry Ingredients India Private Limited is a company under KERRY GROUP P.L.C. Tralee, County Kerry, Ireland. Kerry is the world’s leading taste and nutrition partner for the food, beverage and pharmaceutical markets. Its’ has appx 137 manufacturing locations in 35 countries around the globe, 1.25 billion consumers worldwide. Kerry supplies over 18,000 foods, food ingredients and flavour products to customers in more than 140 countries. Kerry’s leading consumer insights, employees are 23,000+ global RD&A team of 1,100+ food scientists and extensive global footprint enable us to solve our customer’s complex challenges with differentiated solutions. Kerry Group Plc’s last year revenue was INR 72,377 Crore & Profit INR 6,573 Crore. Kerry Group Plc engages in the manufacturing and distribution of food and beverages. It operates through the following segments: Taste & Nutrition; and Consumer Foods. The Taste & Nutrition segment manufactures and distributes an innovative portfolio of taste & nutrition solutions and functional ingredients & actives for the global food, beverage and pharmaceutical industries.

Further, Disclosure pursuant to SEBI Circular no. SEBI/HO/CFD/CFD-PoDI/P/CIR/2023/123 dated July 13, 2023 under Regulation 30 of the SEBI (LODR) Regulations, 2015 is enclosed herewith as “Annexure I”.

You are requested to kindly take the same in your records and oblige us.

Thanking You,

For, Sotac Pharmaceuticals Limited

Sharadkumar Dashrathbhai Patel
Chairman and Managing Director
DIN: 07252252

Place: Ahmedabad

Registered Office:

Plot No. PF/21, Nr. Acme Pharma,
Opp. Teva Pharma, Sanand GIDC - II,
Sanand, Ahmedabad – 382110, Gujarat (INDIA)

CIN: L24230GJ2015PLC085451

Annexure-I

The Disclosure pursuant SEBI Circular no. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023

Sr. No.	Particulars	Details
a)	Name(s) of parties with whom the agreement is entered;	Kerry Ingredients India Private Limited. (An entity under KERRY GROUP P.L.C., Ireland)
b)	Purpose of entering into the agreement;	Sotac Lifesciences Private Limited has entered into agreement with Kerry Ingredients India Private Limited, where SOTAC agreed to manufacture the Products in accordance with the Manufacturing Agreement exclusively for Kerry Ingredients India Private Limited. The Sotac Lifesciences Private Limited hereby accepts such appointment and undertakes to manufacture and supply the Products used for coating of pharmaceutical tablets at the Facility.
c)	Size of agreement;	Approx. Value of Rs. 106 crores (as per part of CCPC margin) over the period of ten years as per the management estimates.
d)	Shareholding, if any, in the entity with whom the agreement is executed;	Nil
e)	Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.	The Term of Manufacturing Agreement is ten (10) years unless terminated earlier as hereinafter provided in Manufacturing Agreement.
f)	Whether, the said parties are related to promoter/promoter group/group companies in any manner. If yes, nature of relationship;	No
g)	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”;	No
h)	In case of issuance of shares to the parties, details of issue price, class of shares issued;	N.A.
i)	in case of loan agreements, details of lender, nature of the loan, total amount of loan granted, total amount outstanding, date of execution of the loan agreement/sanction letter, details of the security provided to the lenders for such loan;	N.A.
j)	Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.;	There exists no actual or potential conflict of interest by and between Sotac Lifesciences Private Limited and any other individual/entity/person concerning the manufacturing of the Product under this agreement.
k)	In case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s): a) name of parties to the agreement; b) nature of the agreement; c) date of execution of the agreement; d) details of amendment and impact thereof or reasons of termination and impact thereof.	NA

For, Sotac Pharmaceuticals Limited.

Sharadkumar Dashrathbhai Patel
Chairman and Managing Director
DIN: 07252252
Place: Ahmedabad

